Chris Boshoff: FDA Approves Our Treatment for Hemophilia A and B for 2 New Patient Populations
Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared on LinkedIn:
”The FDA has approved our treatment for hemophilia A and B for two new patient populations following a priority review.
With this approval, children ages 6 to 11 with hemophilia B will have a subcutaneous, non-factor treatment option available for the first time.
Bringing a medicine discovered and developed by Pfizer to the people who need it most—guided at every step by patient need—is an important moment for our teams.
A special thank you to the Pfizer scientists who are continuing to advance care for people with hemophilia, and to the hemophilia patient community who participated in clinical trials that are instrumental to making advancements like this one happen.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 13:18Cindy Howry: FDA Approves First Treatment for Ataxia-Telangiectasia
-
Sep 20, 2026, 13:08Mohammad Salar Amoli: When Routine Coagulation Tests Miss von Willebrand Disease
-
Sep 20, 2026, 12:55Stelios Andreadis։ Human Salivary Gland Organoids Offer New Potential for Regenerative Medicine
-
Sep 20, 2026, 12:43Obi Light Ogbonnia: The Power of Lived Experience in Sickle Cell Care
-
Sep 20, 2026, 12:34Sabrine Mekni: Advancing HSCT for Children With Fanconi Anemia
-
Sep 20, 2026, 12:11Giacomo Buso: Silent Atherosclerosis Begins Earlier Than Expected
-
Sep 20, 2026, 12:0310 Posts Not to Miss This Week
-
Sep 20, 2026, 11:27Edward Lee Carter: Prasugrel Dosing Matters in P2Y12 Inhibitor Comparisons After PCI
-
Sep 20, 2026, 09:51Ceasovschih Alexandr: A Closer Look at Lipid Disorders in CKM Syndrome